ResMed share price marching higher amid 'significant victory' for ASX 200 healthcare stock

ASX 200 healthcare share ResMed has more than 9,500 issued or pending patents and designs.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price is marching higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed yesterday trading for $24.75. In late morning trade on Tuesday, shares are swapping hands for $24.98 apiece, up 0.9%.

For some context, the ASX 200 is up 0.3% at this same time.

This comes on the heels of a legal victory for the company, which develops and sells digital health technologies and cloud-connected medical devices.

Here's what's happening.

Cropped shot of a young female scientist working on her computer in the laboratory.

Image source: Getty Images

Patent victory for ASX 200 healthcare stock

The ResMed share price is in the green today after the company reported it had won "a significant victory" against New York University (NYU).

ResMed said the United States Patent Trial and Appeals Board has ruled against patent infringement claims lodged by NYU in June 2021.

In its complaint, NYU alleged that the AutoSetTM and AutoRampTM features of ResMed's AirSenseTM 10 AutoSet flow generators, infringed one or more claims of seven NYU patents.

ResMed defended its tech and asserted NYU's claims were invalid. The US Patent Trial judges agreed and have now found that all the challenged claims across the seven patents were invalid.

Commenting on the legal win that looks to be giving the ResMed share price some tailwinds today, Michael Rider, ResMed's global general counsel and secretary said, "We will continue to vigorously defend our innovations."

Rider added:

The fact that our intellectual property contributed to this victory is a testament to our investment in research and development, the hard work of our inventors, and the patent protection we pursue to protect our innovation.

ResMed CEO Mick Farrell said, "Our sustained investment in research and development for over 30 years has culminated in more than 9,500 issued or pending patents and designs."

Farrell applauded the ruling and said ResMed will defend its innovations, "ensuring patients continue to receive our therapy solutions, empowering them to live healthier, higher-quality lives."

ResMed share price snapshot

The ResMed share price is down 18% in 2023.

The past month has seen a positive turn for the ASX 200 healthcare stock, with shares up 11%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Businesswoman with a pleased smile reading on her laptop at a desk in the office with a look of satisfaction.
Healthcare Shares

Are CSL shares dirt cheap and a strong buy?

There is plenty for CSL to prove next week. The current valuation is why I am still interested.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this ASX healthcare stock is a top rebound candidate with big upside 

This could be a perfect buy-low candidate.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

2 ASX healthcare stocks tipped to return 34% to 63%

These companies could be poised for much bigger things.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
ASX Share Market News

Are Pro Medicus shares now too cheap to ignore?

The discount looks tempting, but slowing growth could expose valuation risks.

Read more »

Two ASX share investors sharing a secret.
Healthcare Shares

Cochlear shares are quietly rebounding: Is a bigger rally coming?

After a 58% plunge, Cochlear doesn’t need perfection to surprise investors.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech is tipped to more than double in value

Encouraging trial results have the analysts excited.

Read more »

person climbing mountain
Healthcare Shares

CSL share price forecast: How high could it climb in the next year?

CSL shares could roar back, but investors need more than hope.

Read more »

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »